Most Read Articles
22 Oct 2017
Drinking coffee, whether caffeinated or decaffeinated, is associated with a reduced risk of cardiovascular disease (CVD) and ischaemic heart disease (IHD) mortality in patients with a prior myocardial infarction (MI), according to a recent study.
23 Sep 2018
Supplementation with n−3 or omega-3 fatty acids does not help prevent serious vascular events in diabetic patients without evidence of cardiovascular disease at baseline, according to a study.
Roshini Claire Anthony, 11 Oct 2018

The risk of hospitalization due to heart failure was almost halved in patients with secondary mitral regurgitation who underwent transcatheter mitral valve repair plus medical therapy compared with those who underwent medical therapy alone, according to findings of the COAPT* trial.

07 Jan 2016

According to a Cochrane review, there is moderate evidence to show that fibrates can prevent myocardial infarction (MI) in patients with existing circulatory disease. [2015;10:CD009580. Doi:10.1002/14651858.CD009580.pub2]

Poor insurance coverage, costs keep patients from sticking with PCSK9 inhibitors

10 Jan 2018

Researchers from Duke University in Durham, North Carolina, US, found that up to a third of patients discontinue proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor treatment due to inadequate insurance coverage. [Navar AM, et al, AHA 2017, abstract S2112]

The results were based on a web survey of nearly 800 adults who participated in pharmaceutical company-supported online patient support groups after being prescribed PCSK9 inhibitors.

Most of the participants had tried statins at some point. At the time of the survey, 31 percent of participants were on a statin, 16.7 percent were on a high-intensity statin, and 18.8 percent were taking ezetimibe.

Eighty-seven percent of respondents (n=699) began PCSK9 inhibitor therapy when prescribed. Eighty percent of these respondents received free sample medications at some point. Sixty-six percent of respondents had approved insurance coverage for treatment but while 43 percent reported no co-pay, 16.3 percent reported paying over USD 400 per month out of pocket.

Among those who began PCSK9 inhibitor therapy, 67.7 percent remained on treatment. Those who stopped did so within 1 month (9 percent), 1–3 months (36 percent), 4–6 months (15.8 percent), and after 6 months (39.2 percent), citing insurance approval or re-approval failure (30.5 percent) and high costs (25.5 percent) as reasons.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Oct 2017
Drinking coffee, whether caffeinated or decaffeinated, is associated with a reduced risk of cardiovascular disease (CVD) and ischaemic heart disease (IHD) mortality in patients with a prior myocardial infarction (MI), according to a recent study.
23 Sep 2018
Supplementation with n−3 or omega-3 fatty acids does not help prevent serious vascular events in diabetic patients without evidence of cardiovascular disease at baseline, according to a study.
Roshini Claire Anthony, 11 Oct 2018

The risk of hospitalization due to heart failure was almost halved in patients with secondary mitral regurgitation who underwent transcatheter mitral valve repair plus medical therapy compared with those who underwent medical therapy alone, according to findings of the COAPT* trial.

07 Jan 2016

According to a Cochrane review, there is moderate evidence to show that fibrates can prevent myocardial infarction (MI) in patients with existing circulatory disease. [2015;10:CD009580. Doi:10.1002/14651858.CD009580.pub2]